Comparative Pharmacology
Head-to-head clinical analysis: EVEKEO versus QUILLIVANT XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVEKEO versus QUILLIVANT XR.
EVEKEO vs QUILLIVANT XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.
Extended-release oral suspension formulation of methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their synaptic concentrations. The exact therapeutic effect in ADHD is unknown but is thought to involve dopaminergic and noradrenergic pathways in the prefrontal cortex.
5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.
Initial: 25 mg orally once daily in the morning; may increase weekly in 25 mg increments based on tolerability and response. Maximum: 75 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours. Clinical context: Short half-life supports multiple daily dosing for seizure control. May be prolonged in hepatic impairment.
Approximately 4 hours; extended-release formulation provides therapeutic levels for ~12 hours.
Renal: 30-50% as unchanged drug; fecal: 50-70% as metabolites and unchanged drug.
Primarily renal (approximately 60% as unchanged drug); fecal excretion accounts for <5%.
Category C
Category C
CNS Stimulant
CNS Stimulant